### Direct Regulation of ACTH Secretion by Dopamine

- **Inhibitory effect via dopamine D2 receptors (D2R)**:  
  Dopamine exerts tonic inhibition on ACTH secretion primarily through D2 receptors expressed on corticotroph cells. This is well-established in animal models (especially the intermediate lobe of the pituitary) and has clinical relevance in humans.  
  - In rodents, dopamine strongly inhibits ACTH and α-MSH release from intermediate-lobe melanotropes. During physiological states like lactation, dopamine tone decreases, shifting POMC processing toward ACTH secretion and contributing to stress adaptation.  
  - In humans, D2R are expressed on normal corticotrophs and in 40–80% of ACTH-secreting pituitary adenomas. Dopamine agonists (cabergoline, bromocriptine) suppress ACTH hypersecretion in 20–40% of Cushing’s disease cases and some ectopic ACTH syndromes, often normalizing cortisol and occasionally shrinking tumors.

- **Variable or stimulatory effects in some contexts**:  
  Some studies show dopamine (or D1 receptor stimulation) can enhance ACTH/cortisol responses to certain stimuli, possibly acting at the hypothalamic level to modulate CRH release. L-DOPA can also stimulate cortisol via an ACTH-dependent pathway in specific tests.

### Effects of ACTH on Dopaminergic and Catecholaminergic Systems

- **Upregulation of catecholamine biosynthesis**:  
  ACTH directly increases gene expression of tyrosine hydroxylase (TH, the rate-limiting enzyme for dopamine synthesis) and dopamine β-hydroxylase (DBH, which converts dopamine to norepinephrine) in sympathetic ganglia, locus coeruleus, and adrenal medulla. This occurs via melanocortin receptors (MC2R) and cAMP pathways, independent of adrenal glucocorticoid production.

- **Modulation of dopamine receptors and transmission**:  
  Chronic ACTH treatment increases striatal D2 receptor binding and accelerates adaptive changes in dopamine autoreceptors (e.g., during chronic antidepressant treatment).  
  ACTH fragments (e.g., ACTH1–24, α-MSH) antagonize dopamine-mediated inhibition of striatal dopamine and acetylcholine release.

- **Clinical and pathological observations**:  
  ACTH therapy (e.g., in infantile spasms) reduces elevated dopamine metabolites in CSF. In depression models, ACTH influences mesolimbic dopamine adaptations.

### Indirect or Contextual Links

- **Stress and HPA axis cross-talk**:  
  Acute stress activates both the HPA axis (increasing ACTH) and dopaminergic pathways. Mesocortical dopamine normally exerts negative feedback on HPA activation, while chronic stress can dysregulate both systems.

- **Adrenal medulla interactions**:  
  ACTH administration alters adrenal dopamine levels (via effects on DBH) and may indirectly influence catecholamine release.

In summary, the primary physiological link is **inhibitory** (dopamine → ACTH via pituitary D2R), with clinical exploitation in hypercortisolemic disorders. The reverse direction (ACTH → enhanced dopamine synthesis and modulation of dopaminergic signaling) is prominent in peripheral sympathetic tissues and brain reward/stress circuits. These bidirectional interactions contribute to stress adaptation, energy mobilization, and neuroendocrine plasticity.